Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab before gastrectomy for gastric cancer with peritoneal carcinomatosis
2010-024111-13Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Feb 2011
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and peritoneal carcinomatosis (PC), sponsored by AIO-Studien. Primary endpoint: Macroscopic complete remission of peritoneal carcinomatosis. Started Feb 2011; status: completed.
02
Drugs
catumaxomab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2010-024111-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024111-13.